In the production drugs orient the pharmaceutical companies that have already been thrown into the fight against it coronavirus, with the production of vaccines. The next step in this battle will be the administration of drugs that prevent serious complications. This will also protect people who have not been vaccinated. At the moment, according to a DW report, there is no drug that can be used by everyone.
At present doctors prescribe known and tested drugs, which depending on the onset of the disease, provide some protection. Often patients receive anticoagulants preparations, because o coronavirus increases the risk of blood clots and strokes. They are also sometimes given antibiotics to protect against other infections.
The difficulty lies “in the biology of the virus,” said researcher Emmanuel Wheeler of the Max Delbrook Center for Molecular Biology in an article in the Berliner Zeitung. He notes that “in the case of the flu, the treatment of the virus with drugs starts slowly”. This also applies to coronavirus, which initially starts without symptoms.
Coronavirus drugs: Remdesivir and dexamethanose
At present in cases COVID-19 the substance is administered Remdesivir (brand name Veklury). This is the only treatment so far authorized by the EU for patients at high risk of pneumonia, receiving oxygen at the same time. Originally developed for the Ebola virus, this drug is thought to prevent the coronavirus from multiplying. However, the World Health Organisation (WHO) has the opposite view, while the German Committee of Physicians, Clinics and Health Funds in a report in September states that it sees little benefit from the administration of remedisivir.
Another substance, the dexamethasone, is estimated to suppress the immune response. It has been used for a long time in Germany without formal EU approval. For molecular biologist Wheeler, “this is the basic drug for the treatment of coronavirus.” This substance is indicated for patients in ICU, something that is also recommended by the German Epidemiological Institute Robert Koch. However, in patients with milder symptoms, the use of anti-inflammatory drugs is not indicated.
Antibody formulations are promising
Scientists are also positive about what is being said antibody formulations, eight of which are in the process of being audited by the European Medicines Agency (EMA). Some are already used in Germany in mild cases of coronavirus. In special cases it is administered combination of monoclonal antibodies of companies Regeneron and Roche.
This particular antibody cocktail is the first of which recommends The WHERE for patients with mild symptoms but who are at risk. However, according to the German epidemiologist Christian Drosten, “the delivery of monoclonal antibodies is almost always too late” and specifically when the virus has already penetrated to a large extent in the human body.
However, it also has positive “performance” AstraZeneca AZD7442 antibody cocktail, for which a screening process has also been launched for approval in the EU. Coreper also monitors the effectiveness of two other active ingredients used for other diseases, such as rheumatoid arthritis. Finally, the front page recently became the Molnupiravir flu pill of the American Merck, which has a similar effect to remedisivir, inhibiting the spread of the coronavirus. Merck plans to apply for a license as soon as possible.